Navigation Links
Endologix Announces Favorable Markman Ruling in Cook Patent Litigation

IRVINE, Calif., Aug. 17, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that Judge Tanya Walton Pratt of the United States District Court for the Southern District of Indiana in Indianapolis has issued a Markman ruling in the ongoing patent infringement lawsuit filed against the Company by Cook Medical.

In a Markman ruling, the court determines the meaning of disputed patent claim terms at issue in patent litigation.  After a briefing and oral argument on April 15, 2011 as to the meaning of a number of terms of the claims of the two patents that Cook is asserting in the lawsuit, Judge Pratt adopted many of Endologix's proposed constructions for several terms of claims of both asserted patents, including constructions that the Company considers to be important for the outcome of the case.

The trial date for the patent infringement lawsuit has not yet been set but is expected to be set for fall 2012.

John McDermott, President and Chief Executive Officer of Endologix, commented, "We are pleased with the results of the Markman hearing, remain confident in our position going forward and intend to continue to pursue our numerous defenses."

About Endologix, Inc.Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at

Forward-Looking Statements Except for historical information contained herein, this news release contains forward-looking statements relating to the continuing litigation with Cook Medical.   The achievement of the plans and objectives in such statements involves risks and uncertainties including, but not limited to, risks and uncertainties related to the costs and outcome of intellectual property litigation, many of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.COMPANY CONTACT:


The Ruth GroupJohn McDermott, CEO

Nick Laudico (646) 536-7030(949) 595-7200

Zack Kubow (646)

SOURCE Endologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Endologix Announces First U.S. Implant of AFX™ Endovascular AAA System
2. Endologix to Present at Two Upcoming Conferences
3. Endologix Reports 22% Second Quarter 2011 Revenue Growth
4. Endologix and LeMaitre Vascular Enter Early Termination Agreement for European Distribution Rights of Endologix Products
5. Endologix to Report Second Quarter 2011 Financial Results on July 21, 2011
6. Endologix Announces FDA Approval of AFX™ Endovascular AAA System
7. Endologix to Present at the 2011 Bank of America Merrill Lynch Health Care Conference
8. Endologix Files Form 10-K; Nellix Purchase Price Allocation Finalized
9. Endologix to Present at the ROTH 23rd Annual OC Growth Stock Conference
10. Endologix Reports 41% Fourth Quarter 2010 Revenue Growth
11. Endologix Announces Presentation of Favorable Initial PEVAR Trial Results
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... "When I was traveling, I was very ... "Many people catch diseases simply from sitting on such dirty toilet seats. I ... germs." , He developed the patent-pending QUDRATECS to eliminate the need to sit ...
(Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... Health-E-minds, an innovative online platform for mental health and wellness consultation, has collaborated ... This partnership will bridge the knowledge gap experienced by parents and bring advice ...
(Date:11/27/2015)... , ... November 27, 2015 , ... Dr. Thomas ... Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph ... that both STEMI and Sepsis conditions present in similar ways and require time-critical intervention ...
Breaking Medicine News(10 mins):